ML279
ML279 is a potent scavenger receptor, class B, type I (SR-BI) inhibitor. ML279 can inhibit SR-BI-mediated lipid uptake by stabilizing the binding of HDL to SR-BI (EC50 = 0.27 μM). ML279 can be used for the researches of infection and cardiovascular disease, such as atherosclerosis and HCV infection.
For research use only. We do not sell to patients.
- CAS No.: 1604821-55-7
- Formula: C24H32N6O4
- Molecular Weight:468.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.27 μM
Compound: 5e, ML279
|
Inhibition of mouse SR-BI isoform 1 expressed in CHO cells assessed as increase in binding of Alexa-488-labeled HDL particles to cells
Inhibition of mouse SR-BI isoform 1 expressed in CHO cells assessed as increase in binding of Alexa-488-labeled HDL particles to cells
|
[PMID: 25958245] |
| CHO | IC50 |
0.005 μM
Compound: 5e, ML279
|
Inhibition of mouse SR-BI isoform 1 expressed in CHO cells assessed as reduction in uptake of [3H]CE from [3H]CE-HDL by by liquid scintillation counting method
Inhibition of mouse SR-BI isoform 1 expressed in CHO cells assessed as reduction in uptake of [3H]CE from [3H]CE-HDL by by liquid scintillation counting method
|
[PMID: 25958245] |
| CHO | IC50 |
0.005 μM
Compound: ML279
|
Inhibition of mouse SR-B1 overexpressed in CHO cells assessed as inhibition of [3H]cholesteryl ester uptake into cells after 2 to 3 hrs by liquid scintillation counting
Inhibition of mouse SR-B1 overexpressed in CHO cells assessed as inhibition of [3H]cholesteryl ester uptake into cells after 2 to 3 hrs by liquid scintillation counting
|
[PMID: 25900219] |
| CHO | IC50 |
0.017 μM
Compound: 5e, ML279
|
Inhibition of mouse SR-BI isoform 1 expressed in CHO cells assessed as reduction in transfer of fluorescent lipid DiI from human HDL particles into cells by fluorescence assay
Inhibition of mouse SR-BI isoform 1 expressed in CHO cells assessed as reduction in transfer of fluorescent lipid DiI from human HDL particles into cells by fluorescence assay
|
[PMID: 25958245] |
Chemical Information
-
CAS No. 1604821-55-7
-
Molecular Weight 468.55
-
Formula C24H32N6O4
-
SMILES
O=C(N(C1CCCCC1)[C@H](C)C(NC2CCCC2)=O)CN3N=C(C4=CC=C(OCO5)C5=C4)N=N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)